Skip to main content
OpenTrials
Completed

NCT Number: NCT05820555

The Goodnight Screen Media Study

To test the timing of evening tablet use on children's circadian phase and sleep (i.e., sleep onset and sleep duration) compared to no screen media use. To explore the effect of evening tablet use on children's inhibitory control and executive function.

Completed

Looking for future studies?

Notify Me

Key information

Age range

48 month–59 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Children's Nutrition Research Center

Houston, Texas, 77030, United States

About this study

The goal of the study is to test the effect of tablet use before bed on the sleep, circadian phase, and executive functioning (EF) of 4-year-olds using a 3-group randomized controlled trial in which children are assigned to receive one of 2 experimental conditions (Group A:1 hour of tablet use in the hour before bed; Group B:1 hour of tablet use 2 hours before bed) or a control condition (no evening screen media use). It is hypothesized that in comparison to no tablet use, daily exposure to tablet use before bed will be associated with a delay in children's circadian phase (e.g., occurring later in the evening/night), a longer sleep latency (i.e., later sleep onset), and shorter sleep duration. It is anticipated that tablet use in the hour before bed will have a greater impact on children's circadian phase and sleep than tablet use 2 hours before bed, or no tablet use before bed. We will explore whether changes in circadian phase and sleep result in poorer performance on measures of EF (i.e., inhibitory control and working memory).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • preschool-aged children (4.0 to <5.0 years old) and their parent
  • living in the Greater Houston area.
  • parent must be a biological parent or legal guardian who lives with the child ≥50% of the time and has a primary role of caring for the child
  • parent is comfortable participating in the study and responding to questionnaires in English.
  • The child does not have to have access to mobile device, but if they do, the primary device they use has to be an Android OS ≥5.0 either used only by the study child or shared with others, or an Apple iOS ≥14.0 that only the child uses.
  • Parent and child must be fluent in English.

Exclusion criteria

  • The child has a chronic medical condition or takes a medication affecting sleep, or circadian rhythms (e.g., melatonin supplementation, diagnosed sleep disorder, steroid use, etc.) or a diagnosed cognitive or learning impairment affecting EF (e.g., attention deficit hyperactivity disorder).
  • Child with blindness or significant vision problems that impacts both screen media use and sleep.

Treatment and study plan

Timed evening technology and digital media use (tablet use)

Behavioral

timing of children's evening tablet device use relative to bedtime

no technology and digital media use (screen media use)

Behavioral

no screen media use relative to bedtime (Tablets, computers, TV, moble devices, smart phone)

Primary outcomes

  1. Change in Dim light Melatonin Onset Phase

    Time frame: Day 7 to Day 14

    Circadian phase can be examined by measuring the circadian timing of melatonin onset under dim light conditions (dim light melatonin onset; DMLO). Compared to markers of endogenous circadian rhythms, melatonin is relatively robust. Salivary DLMO measures have demonstrated high intraclass correlations (.93) with plasma and sensitivity and specificity comparable to plasma assays. Following established procedures with children, salivary DLMO will be collected on a in the laboratory under dim light conditions (<5 lux), via a cheek swab every 30-60 minutes beginning 5 hours prior to and ending 1-hour following typical bedtime. Saliva samples will be centrifuged, frozen, and assayed using radioimmunoassay test kits by Solid Phase in Portland Me. DLMO phase will be determined using linear interpolation across the time points before and after melatonin concentration increased to and remained above 4pg/mL.

  2. Change in Dim light Melatonin Onset Phase

    Time frame: Day 14 to Day 21

    Circadian phase can be examined by measuring the circadian timing of melatonin onset under dim light conditions (dim light melatonin onset; DMLO). Compared to markers of endogenous circadian rhythms, melatonin is relatively robust. Salivary DLMO measures have demonstrated high intraclass correlations (.93) with plasma and sensitivity and specificity comparable to plasma assays. Following established procedures with children, salivary DLMO will be collected on a in the laboratory under dim light conditions (<5 lux), via a cheek swab every 30-60 minutes beginning 5 hours prior to and ending 1-hour following typical bedtime. Saliva samples will be centrifuged, frozen, and assayed using radioimmunoassay test kits by Solid Phase in Portland Me. DLMO phase will be determined using linear interpolation across the time points before and after melatonin concentration increased to and remained above 4pg/mL.

Secondary outcomes

  1. Change in the Average Sleep Onset

    Time frame: Day 1 through 6 to Day 9 through Day 13

    Actigraphs (GT3X-BT, Pensacola, FL) worn on the wrist of the non dominant hand 24 hours a day for 4-5 days will measure sleep duration and timing of sleep onset and waking. Wrist placement reliably measures sleep duration. Sleep diaries will be completed. Monitor-wear logs will identify times the accelerometer is removed and the activity engaged in while the monitor is off.

  2. Change in the Average Sleep Onset

    Time frame: Day 9 through 13 and Day 16 through 20

    Actigraphs (GT3X-BT, Pensacola, FL) worn on the wrist of the non dominant hand 24 hours a day for 4-5 days will measure sleep duration and timing of sleep onset and waking. Wrist placement reliably measures sleep duration. Sleep diaries will be completed. Monitor-wear logs will identify times the accelerometer is removed and the activity engaged in while the monitor is off.

  3. Change in Average Sleep duration

    Time frame: Day 1 through 6 to Day 9 through Day 13

    Actigraphs (GT3X-BT, Pensacola, FL) worn on the wrist of the non dominant hand 24 hours a day for 4-5 days will measure sleep duration and timing of sleep onset and waking. Wrist placement reliably measures sleep duration. Sleep diaries will be completed. Monitor-wear logs will identify times the accelerometer is removed and the activity engaged in while the monitor is off.

  4. Change in Average Sleep duration

    Time frame: Day 9-13 and Day 16-20

    Actigraphs (GT3X-BT, Pensacola, FL) worn on the wrist of the non dominant hand 24 hours a day for 4-5 days will measure sleep duration and timing of sleep onset and waking. Wrist placement reliably measures sleep duration. Sleep diaries will be completed. Monitor-wear logs will identify times the accelerometer is removed and the activity engaged in while the monitor is off.

  5. Change in Inhibitory Control-Day/Night

    Time frame: Day 14 or Day 21

    Children's inhibitory control will be assessed using the Day/Night task. The order of this task will be counterbalanced across Day 14 and 21. This task can be used interchangeably with Grass/snow, so we will examine the difference in performance from the test administered on day 14 to the test administered on day 21.

  6. Change in Inhibitory Control-Grass/Snow

    Time frame: Day 14 or Day 21

    Children's inhibitory control will be assessed using the Grass/Snow. The order of this task will be counterbalanced across Day 14 and 21. This task can be used interchangeably with Grass/snow, so we will examine the difference in performance from the test administered on day 14 to the test administered on day 21.

  7. Change in Working memory

    Time frame: Day 14 to Day 21

    Children's Working Memory will be assessed using the Missing Scan assessment. This task will be administered at Day 14 and 21.

  8. Change in Working memory

    Time frame: Day 14 to Day 21

    Children's Working Memory will be assessed using the Spin the Pots assessment. This task will be administered at Day 14 and 21.

  9. Change in combined assessment of Executive Functioning working memory and inhibitory control

    Time frame: Day 14 to Day 21

    The Head-Toes-Knees-Shoulder Task assesses both working memory and inhibitory control and will be administered on Day 14 and Day 21.

Other outcomes

  1. Ambient Light Exposure

    Time frame: Days 1-21

    ActLumus devices containing a photocell will be used to assess ambient light exposure. Devices will be pinned to the shirt. ActLumus devices are capable of assessing light intensity and wavelength. Light exposure will be used as a covariate in analyses.

  2. Average daily duration of Tablet use (excluding the experimental exposures)

    Time frame: Days 1-21

    Children's tablet use on Android and iOS devices will be assessed during the study period. Daily screen use will be used as a covariate in the analysis. The Chronicle app will be used to assess the timing and amount of children's Android device use. Code developed by Arcascope will be used to assess the amount of children's iOS device usage.

  3. Percentage of time that children followed the screen media use guidelines for their condition during week 2

    Time frame: Days 8-13

    The Chronicle and Acrascope data will be used to assess adherence to the evening tablet use conditions.

  4. Percentage of time that children followed the screen media use guidelines for their condition during week 3

    Time frame: Days 15-20

    The Chronicle and Acrascope data will be used to assess adherence to the evening tablet use conditions.

  5. Children's Sleep Hygiene Scale (total score)

    Time frame: Day 7

    Sleep hygiene will be assessed by parent report on the Children's Sleep Hygiene Scale. Contains 22 items. Response options are scored as follows: Never (1 point); Once in Awhile (2 points); Sometimes (3 points); Quite Often (4 points); Frequently, if not Always (5 points); Always (6 points). It contains 6 subscales that are computed by computing the mean of the items (each subscale could range from 1-6). The total score is computed by computing the mean of the subscales, with a potential range of 1-6. The total score will be used as the outcome of interest in the current study. Higher scores indicate better sleep hygiene practices.

  6. The Children's Chronotype Questionnaire

    Time frame: Day 7

    Chronotype will be assessed by parent report of the child's preference for morningness or eveningness. The M/E score is calculated by adding items 17-26 (responses scored as a=1, b=2, c=3, d=4, d=5), except items 17,18,24,25 are reverse scored. the M/E score ranges from 10 (extreme morningness) to 49 (extreme eveningness). Morning types are defined as having a M/E scale score of ≤23, intermediate types: score of 24-32, and evening types: score ≥33.

  7. Children's Sleep Habits Questionnaire

    Time frame: Day 7

    Parents will be asked to report children's sleep behaviors and problems on the Child Sleep Habits Questionnaire. The total sleep disturbance score is comprised of 33 items. Response options are scored as Usually = 3; Sometimes = 2; and Never/Rarely = 1. Scores range from 33 to 99. Higher scores indicate more sleep problems.

Sponsors and collaborators

Lead sponsor

Baylor College of Medicine

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • University of Nevada, Reno
  • William Marsh Rice University

Registry information

Official study title

Experimental Effects of Children's Evening Media Use on Circadian Phase, Sleep and Executive Functioning

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Apr 19, 2023
Registry last updated
Jun 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.